Supplemental Table 1. Crude and Adjusted Associations of Patient Characteristics with Average Yearly Change in MAXIMAL COMMON CAROTID IMT (µm/year)

_____

	Model 1 (Univariate)		Model 2 (Extended)		Model 3 (Simplified)		Model 4	
	β	(95% CI)	β	(95% CI)	β	(95% CI)	β	(95% CI)
Male (vs. female)	5.1	(-2.5, 12.8)***	- 0.8	(-9.9, 8.4)				
Exercise (per 30 minutes/day)	2.2	(0.6, 3.8)*	1.7	(0.1, 3.3)*	1.9	(0.4, 3.5)*		
Current smoking	7.0	(-5.8, 19.8)***	12.4	(0.3, 24.6)*	12.6	(0.7, 24.4)*	10.9	(-0.7, 22.4)**
Baseline body surface area (BSA), per m^2	19.8	(3.4, 36.3)*	13.7	(-4.9, 32.2)**	15.1	(-0.6, 30.9)**	18.2	(2.4, 34.0)*
Baseline LDL, per 20 mg/dL	- 2.2	(-4.5, 0.1)*	- 1.7	(-4.0, 0.6)				
log Baseline CCA-IMT	- 12.8	(-34.7, 9.1)***	- 19.8	(-43.0, 3.4)**	- 19.2	(-39.9, 1.5)**	- 16.9	(-37.8, 3.9)**
RA duration: 1st tertile (6 months to 6 years)	referent	---------	referent	----------	referent	----------	referent	----------
2nd tertile (7 to 14 years)	- 13.0	(-21.7, -4.3)*	- 12.9	(-21.5, -4.3)*	- 13.5	(-21.9, -5.1)*	- 14.7	(-23.1, -6.2)*
3rd tertile (≥ 15 years)	- 11.8	(-20.3, -3.4)*	- 10.6	(-19.0, -2.1)*	- 10.5	(-18.5, -2.4)*	- 12.0	(-20.1, -3.8)*
Any SE alleles	2.8	(-5.5, 11.1)						
Tender joint count, per joint (square root transformed)	- 3.0	(-5.4, -0.7)*	- 2.5	(-5.1, 1.0)				
Average IL-6 level during the study (per ng/mL)	- 0.1	(-0.3, 0.1)						
Baseline HAQ	- 6.0	(-11.1, -0.9)*	0.7	(-5.4, 6.8)				
Baseline TNF inhibitor use	- 7.7	(-15.1, -0.3)*	- 6.4	(-13.6, 0.8)**	- 7.8	(-14.7, -1.0)*	- 7.8	(-14.7, -0.9)*

*   p < 0.05
**   0.10 > p > 0.05
***   0.20 > p > 0.10

β coefficients represent the change in the outcome per unit increase in the predictor

IMT=intima-medial thickness; CI=confidence interval; LDL=large density lipoprotein; RA=rheumatoid arthritis; IL=interleukin; SE=shared epitope; HAQ=Health Assessment Questionnaire; TNF=tumor necrosis factor

Supplemental Table 2. Crude and Adjusted Associations of Patient Characteristics with Average Yearly Change in MAXIMAL INTERNAL CAROTID IMT (μm/year)

_____

	Model 1 (Univariate)		Model 2 (Extended)		Model 3 (Simplified)		Model 4	
	β	(95% CI)	β	(95% CI)	β	(95% CI)	β	(95% CI)
Male	41.0	(14.5, 67.4)*	16.8	(-15.9, 49.6)				
Exercise (per 30 minutes/day)	8.1	(2.8, 13.4)*	6.7	(1.2, 12.2)*	7.6	(2.3, 12.9)*		
Ever smoking	31.2	(5.4, 57.0)*	21.4	(-5.6, 48.5)***	25.5	(-0.3, 51.2)**	23.8	(-3.6, 51.1)**
Baseline body surface area (BSA), per m^2	70.4	(11.3, 129.5)*	38.9	(-30.0, 108)***	58.7	(-0.8, 118)**	66.3	(4.5, 128.0)*
Hypertension	9.0	(-17.8, 35.8)						
Baseline LDL, per 20 mg/dL	3.0	(-5.4, 11.4)						
log Baseline ICA-IMT	34.2	(1.4, 67.0)*	7.3	(-28.1, 42.7)				
Tender joint count, per joint (square root transformed)	-6.4	(-14.7, 1.9)						
Average IL-6 level during the study (per ng/mL)	0.1	(-0.6, 0.7)						
Cumulative prednisone at V1	1.7	(0.4, 3.0)*	1.2	(0.1, 2.5)*	1.2	(0.1, 2.4)*	1.7	(0.5, 3.0)*
Current methotrexate at V1	-10.9	(-38.3, 16.4)						

* $p < 0.05$
** $0.10 > p > 0.05$
*** $0.20 > p > 0.10$

β coefficients represent the change in the outcome per unit increase in the predictor

IMT=intima-medial thickness; CI=confidence interval; LDL=large density lipoprotein; IL=interleukin; SE=shared epitope; V1=study visit 1